Treatment Outcome and Prognostic Factors for Rheumatoid Arthritis (RA) Patients With Interstitial Lung Disease (ILD)
NCT ID: NCT03099525
Last Updated: 2020-06-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
600 participants
OBSERVATIONAL
2016-10-31
2022-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
NCT03297775
Deciphering Rheumatoid Arthritis-associated Interstitial Lung Disease Pathogenesis 2
NCT04227535
Investigation on Risk Factors of Rheumatoid Arthritis Related Interstitial Lung Disease
NCT06036537
Interstitial Lung Disease in Early Rheumatoid Arthritis
NCT03977415
Factors of ILD in Newly Diagnosed Rheumatoid Arthritis
NCT04002765
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
: Comparison of prognosis between RA-ILD and RA-non ILD patients
Secondary objectives
1. Identification of the prognostic factors or aggravation factors of ILD in RA-ILD patients
2. Identification of the association between ILD and autoantibody profiles in RA-ILD patients
3. Comparison of RA disease activity control between RA-ILD and RA-non ILD patients using disease activity score (DAS)28-erythrocyte sedimentation ratio (ESR), DAS28 C-reactive protein (CRP), simple disease activity index (SDAI) and clinical disease activity index (CDAI)
4. Comparison of biologic and non-biologic DMARD treatment response in RA-ILD patients using disease activity parameters
The study population will be adult RA patients who have checked a chest computed tomography (CT) scan within 2 years of enrollment. No additional visits or laboratory tests will be done outside the routine clinical practice for RA-non ILD patients. For RA-ILD patients, high resolution computed tomography (HRCT), pulmonary function test (PFT) and 6-min walk test will be examined annually to identify the progression of ILD. Selection of medication including conventional DMARDs, biologic DMARDs, glucocorticoid, and inhaler, dosing and treatment duration are at the discretion of the investigator.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RA-ILD
Patients who are diagnosed with ILD. No intervention in this study.
ILD
This is an observational study without any intervention.
RA-non ILD
Patients who are not diagnosed with ILD. No intervention in this study.
ILD
This is an observational study without any intervention.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ILD
This is an observational study without any intervention.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who are more than 19 years old
* Patients who have checked chest CT scanning within 2 years
* Patients who provide a written consent of participating in this study
Exclusion Criteria
* Patients who are pregnant
* Patients who dose not provide a written consent of participating in this study
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hanyang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yoon-Kyoung Sung
Associate professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yoon-Kyoung Sung, MD,PhD,MPH
Role: PRINCIPAL_INVESTIGATOR
Hanyang University Hospital for Rheumatic Diseases
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hanyang University
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Kim H, Cho SK, Song YJ, Kang J, Jeong SA, Kim HW, Choi CB, Kim TH, Jun JB, Bae SC, Yoo DH, Lee H, Park DW, Sohn JW, Yoon HJ, Hong SJ, Yoo SJ, Choi YW, Lee Y, Kim SH, Sung YK. Clinical characteristics of rheumatoid arthritis patients with interstitial lung disease: baseline data of a single-center prospective cohort. Arthritis Res Ther. 2023 Mar 17;25(1):43. doi: 10.1186/s13075-023-03024-8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HUHRD-SPE-16-08
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.